Previous 10 | Next 10 |
2024-05-22 11:25:25 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk office building fire brought under c...
2024-05-22 10:01:06 ET More on NeuroBo Pharmaceuticals NeuroBo Phase 2a study for MASH drug to proceed as planned NeuroBo stock jumps 14% on weight-loss drug update Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for Ne...
2024-05-22 08:13:08 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Australia to ban copycat versions of weight loss ...
2024-05-22 07:51:38 ET More on Hims & Hers Health Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead 10 Solid Reasons To Buy Hims & Hers Stock Hims & Hers: Strong Operating Leverage And Profitability Inflection ...
2024-05-22 07:14:37 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Study finds 30% of Wegovy, Sax...
2024-05-21 14:06:23 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk unsure when it will meet obesity dru...
2024-05-21 11:50:45 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Microcap Mangoceuticals doubles on plan to sell c...
2024-05-21 10:29:09 ET More on Weight Loss Drugs Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead Genetics may determine who responds well to Wegovy: report One in eight U.S. adults admits to GLP-1 usage as public aware...
2024-05-21 09:21:57 ET More on Eli Lilly, Novo Nordisk Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Eli Lilly inks radiopharma deal wort...
2024-05-21 06:43:02 ET Eli Lilly ( NYSE: LLY ) has secured China approval for its blockbuster drug tirzepatide for use in treating diabetes.... Read the full article on Seeking Alpha For further details see: Eli Lilly’s tirzepatide cleared for diabetes treatme...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...
2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...